Ana Belén Carrillo-Gálvez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Belén Carrillo-Gálvez has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Federico Zurita
Department of Genetics, University of Granada, Granada, Spain
3 shared publications- Francisco Ovalle
Department of Pathology School of Medicine, University of Granada Granada Spain
3 shared publications - Miguel Padial-Molina
Department of Oral Surgery and Implant Dentistry School of Dentistry, University of Granada Granada Spain
3 shared publications - Natividad Martin-Morales
Department of Oral Surgery and Implant Dentistry, School of Dentistry University of Granada Granada Spain
3 shared publications - Pablo Galindo-Moreno
Department of Oral Surgery and Implant Dentistry School of Dentistry, University of Granada Granada Spain
3 shared publications Allinson Olaechea
Department of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain
2 shared publications
Latest Publications
- Open Access
- 9 June 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-16
Cross-talk between NLRP3 and AIM2 inflammasomes in macrophage activation by LPS and titanium ions
Background: Periodontitis and peri-implantitis are chronic inflammatory diseases that contribute to tissue destruction and bone loss. Periodontitis is triggered by pathogenic bacteria, while peri-implantitis also involves metallic particles, which increase the inflammatory response. Both conditions are linked to the activation of inflammasomes, such as NLRP3 and AIM2, which facilitate the release of pro-inflammatory cytokines like IL-1β and IL-18 and induce pyroptosis. This study aims to investigate the activation of NLRP3 and AIM2 inflammasomes in macrophages exposed to bacterial and metallic components, as well as to explore the potential interplay between these two signaling pathways. Methods: Human THP-1-derived macrophages were treated with bacterial lipopolysaccharide (LPS) and titanium ions to evaluate inflammasome activation. IL-1β secretion, ROS production, mitochondrial DNA release and pyroptosis were assessed. Additionally, macrophages deficient in NLRP3 and AIM2 were used to examine the roles of these inflammasomes in inflammatory responses. Results: LPS and titanium ions synergistically activated NLRP3, resulting in increased IL-1β secretion, ROS production, and pyroptosis. Under these conditions, AIM2 was indirectly activated, as indicated by elevated mitochondrial DNA release. Notably, AIM2 expression was reduced in wild-type macrophages treated with LPS and titanium ions compared to LPS alone, however, in NLRP3-deficient cells, AIM2 expression was increased following LPS and titanium ions treatment. This upregulation of AIM2 in NLRP3-deficient cells was further reduced by ROS inhibition, which decreased mitochondrial DNA release. Additionally, NLRP3 knockout had a more pronounced effect on reducing IL-1β secretion and pyroptosis compared to AIM2 knockout, indicating a greater role of NLRP3 in these inflammatory responses. Conclusions: This study demonstrates that bacterial and metallic components drive the activation of both NLRP3 and AIM2 inflammasomes in macrophages, highlighting their roles in the inflammatory responses associated with periodontitis and peri-implantitis. The findings reveal a regulatory relationship between NLRP3 and AIM2, where the absence of one inflammasome can enhance the activity of the other. These results provide new insights into the mechanisms underlying inflammasome-mediated inflammation and suggest potential therapeutic targets for managing inflammatory diseases.
- 9 June 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-16
Open AccessCross-talk between NLRP3 and AIM2 inflammasomes in macrophage activation by LPS and titanium ions
Background: Periodontitis and peri-implantitis are chronic inflammatory diseases that contribute to tissue destruction and bone loss. Periodontitis is triggered by pathogenic bacteria, while peri-implantitis also involves metallic particles, which increase the inflammatory response. Both conditions are linked to the activation of inflammasomes, such as NLRP3 and AIM2, which facilitate the release of pro-inflammatory cytokines like IL-1β and IL-18 and induce pyroptosis. This study aims to investigate the activation of NLRP3 and AIM2 inflammasomes in macrophages exposed to bacterial and metallic components, as well as to explore the potential interplay between these two signaling pathways. Methods: Human THP-1-derived macrophages were treated with bacterial lipopolysaccharide (LPS) and titanium ions to evaluate inflammasome activation. IL-1β secretion, ROS production, mitochondrial DNA release and pyroptosis were assessed. Additionally, macrophages deficient in NLRP3 and AIM2 were used to examine the roles of these inflammasomes in inflammatory responses. Results: LPS and titanium ions synergistically activated NLRP3, resulting in increased IL-1β secretion, ROS production, and pyroptosis. Under these conditions, AIM2 was indirectly activated, as indicated by elevated mitochondrial DNA release. Notably, AIM2 expression was reduced in wild-type macrophages treated with LPS and titanium ions compared to LPS alone, however, in NLRP3-deficient cells, AIM2 expression was increased following LPS and titanium ions treatment. This upregulation of AIM2 in NLRP3-deficient cells was further reduced by ROS inhibition, which decreased mitochondrial DNA release. Additionally, NLRP3 knockout had a more pronounced effect on reducing IL-1β secretion and pyroptosis compared to AIM2 knockout, indicating a greater role of NLRP3 in these inflammatory responses. Conclusions: This study demonstrates that bacterial and metallic components drive the activation of both NLRP3 and AIM2 inflammasomes in macrophages, highlighting their roles in the inflammatory responses associated with periodontitis and peri-implantitis. The findings reveal a regulatory relationship between NLRP3 and AIM2, where the absence of one inflammasome can enhance the activity of the other. These results provide new insights into the mechanisms underlying inflammasome-mediated inflammation and suggest potential therapeutic targets for managing inflammatory diseases.
- Open Access
- 10 March 2025
- Published by Wiley in Clinical Oral Implants Research
- Vol. 36 (7) , 802-820
Evolution in the Peri‐Implant Oral Microbiome and Their Relationship to Long‐Term Marginal Bone Loss: A Randomized Clinical Study
Objectives: To analyze the clinical, radiographic, and microbiological changes around implants with a multiphosphonate‐treated surface, prosthetically loaded with two different protocols after 5 years of functional loading. Material and Methods: A randomized clinical trial was designed to initiate prosthetic loading over single dental implants after 8 (control) or 4 weeks (test). Several variables were analyzed, including patients' level variables, intrasulcular biofilm, and marginal bone level at several time points, from 1 to 60 months after loading. Results: A total of 23 patients attended the 5‐year follow‐up visit. No clinical variable changed over time, except mucosal thickness from dental impressions to prosthesis delivery. No significant radiographic differences were observed either over time or between groups. Microbiologically, there was a change in the microbiome from the constitution of the biological width to the final follow‐up. Seven species changed significantly, with a significant increase in Porphyromonas gingivalis and Tannerella forsythia from 12 to 60 months and a decrease in the other species. However, changes in the relative abundance of species over time, whether increasing or decreasing, did not show a correlation with marginal bone loss. Conclusion: Implants with a multiphosphonate‐treated surface showed no differences in clinical and radiographic variables after 5 years of function, regardless of the prosthetic loading protocol used. From a microbiological point of view, although there was an evolution of the microbiome in the peri‐implant sulcus towards Socransky's red circle pathogenic bacteria, no microorganism showed a significant correlation with the radiographic changes produced in the peri‐implant bone over time. Trial Registration: ClinicalTrials.gov identifier: NCT03059108
- 10 March 2025
- Published by Wiley in Clinical Oral Implants Research
- Vol. 36 (7) , 802-820
Open AccessEvolution in the Peri‐Implant Oral Microbiome and Their Relationship to Long‐Term Marginal Bone Loss: A Randomized Clinical Study
Objectives: To analyze the clinical, radiographic, and microbiological changes around implants with a multiphosphonate‐treated surface, prosthetically loaded with two different protocols after 5 years of functional loading. Material and Methods: A randomized clinical trial was designed to initiate prosthetic loading over single dental implants after 8 (control) or 4 weeks (test). Several variables were analyzed, including patients' level variables, intrasulcular biofilm, and marginal bone level at several time points, from 1 to 60 months after loading. Results: A total of 23 patients attended the 5‐year follow‐up visit. No clinical variable changed over time, except mucosal thickness from dental impressions to prosthesis delivery. No significant radiographic differences were observed either over time or between groups. Microbiologically, there was a change in the microbiome from the constitution of the biological width to the final follow‐up. Seven species changed significantly, with a significant increase in Porphyromonas gingivalis and Tannerella forsythia from 12 to 60 months and a decrease in the other species. However, changes in the relative abundance of species over time, whether increasing or decreasing, did not show a correlation with marginal bone loss. Conclusion: Implants with a multiphosphonate‐treated surface showed no differences in clinical and radiographic variables after 5 years of function, regardless of the prosthetic loading protocol used. From a microbiological point of view, although there was an evolution of the microbiome in the peri‐implant sulcus towards Socransky's red circle pathogenic bacteria, no microorganism showed a significant correlation with the radiographic changes produced in the peri‐implant bone over time. Trial Registration: ClinicalTrials.gov identifier: NCT03059108
- Open Access
- 22 January 2025
- Published by Springer Nature in Research Square
Cross-talk Between NLRP3 and AIM2 Inflammasomes in Macrophage Activation by LPS and Titanium Ions
Background Periodontitis and peri-implantitis are chronic inflammatory diseases that contribute to tissue destruction and bone loss. Periodontitis is triggered by pathogenic bacteria, while peri-implantitis also involves metallic particles, which increase the inflammatory response. Both conditions are linked to the activation of inflammasomes, such as NLRP3 and AIM2, which facilitate the release of pro-inflammatory cytokines like IL-1β and IL-18 and induce pyroptosis. This study aims to investigate the activation of NLRP3 and AIM2 inflammasomes in macrophages exposed to bacterial and metallic components, as well as to explore the potential interplay between these two signaling pathways. Methods Human THP-1-derived macrophages were treated with bacterial lipopolysaccharide (LPS) and titanium ions to evaluate inflammasome activation. IL-1β secretion, ROS production, mitochondrial DNA release and pyroptosis were assessed. Additionally, macrophages deficient in NLRP3 and AIM2 were used to examine the roles of these inflammasomes in inflammatory responses. Results LPS and titanium ions synergistically activated NLRP3, resulting in increased IL-1β secretion, ROS production, and pyroptosis. Under these conditions, AIM2 was indirectly activated, as indicated by elevated mitochondrial DNA release. Notably, AIM2 expression was reduced in wild-type macrophages treated with LPS and titanium ions compared to LPS alone, however, in NLRP3-deficient cells, AIM2 expression was increased following LPS and titanium ions treatment. This upregulation of AIM2 in NLRP3-deficient cells was further reduced by ROS inhibition, which decreased mitochondrial DNA release. Additionally, NLRP3 knockout had a more pronounced effect on reducing IL-1β secretion and pyroptosis compared to AIM2 knockout, indicating a greater role of NLRP3 in these inflammatory responses. Conclusions This study demonstrates that bacterial and metallic components drive the activation of both NLRP3 and AIM2 inflammasomes in macrophages, highlighting their roles in the inflammatory responses associated with periodontitis and peri-implantitis. The findings reveal a regulatory relationship between NLRP3 and AIM2, where the absence of one inflammasome can enhance the activity of the other. These results provide new insights into the mechanisms underlying inflammasome-mediated inflammation and suggest potential therapeutic targets for managing inflammatory diseases.
- 22 January 2025
- Published by Springer Nature in Research Square
Open AccessCross-talk Between NLRP3 and AIM2 Inflammasomes in Macrophage Activation by LPS and Titanium Ions
Background Periodontitis and peri-implantitis are chronic inflammatory diseases that contribute to tissue destruction and bone loss. Periodontitis is triggered by pathogenic bacteria, while peri-implantitis also involves metallic particles, which increase the inflammatory response. Both conditions are linked to the activation of inflammasomes, such as NLRP3 and AIM2, which facilitate the release of pro-inflammatory cytokines like IL-1β and IL-18 and induce pyroptosis. This study aims to investigate the activation of NLRP3 and AIM2 inflammasomes in macrophages exposed to bacterial and metallic components, as well as to explore the potential interplay between these two signaling pathways. Methods Human THP-1-derived macrophages were treated with bacterial lipopolysaccharide (LPS) and titanium ions to evaluate inflammasome activation. IL-1β secretion, ROS production, mitochondrial DNA release and pyroptosis were assessed. Additionally, macrophages deficient in NLRP3 and AIM2 were used to examine the roles of these inflammasomes in inflammatory responses. Results LPS and titanium ions synergistically activated NLRP3, resulting in increased IL-1β secretion, ROS production, and pyroptosis. Under these conditions, AIM2 was indirectly activated, as indicated by elevated mitochondrial DNA release. Notably, AIM2 expression was reduced in wild-type macrophages treated with LPS and titanium ions compared to LPS alone, however, in NLRP3-deficient cells, AIM2 expression was increased following LPS and titanium ions treatment. This upregulation of AIM2 in NLRP3-deficient cells was further reduced by ROS inhibition, which decreased mitochondrial DNA release. Additionally, NLRP3 knockout had a more pronounced effect on reducing IL-1β secretion and pyroptosis compared to AIM2 knockout, indicating a greater role of NLRP3 in these inflammatory responses. Conclusions This study demonstrates that bacterial and metallic components drive the activation of both NLRP3 and AIM2 inflammasomes in macrophages, highlighting their roles in the inflammatory responses associated with periodontitis and peri-implantitis. The findings reveal a regulatory relationship between NLRP3 and AIM2, where the absence of one inflammasome can enhance the activity of the other. These results provide new insights into the mechanisms underlying inflammasome-mediated inflammation and suggest potential therapeutic targets for managing inflammatory diseases.
- Open Access
- 16 July 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (8) , 826-841
NLRP3 and AIM2 inflammasomes expression is modified by LPS and titanium ions increasing the release of active IL-1β in alveolar bone-derived MSCs
Periodontitis and peri-implantitis are inflammatory diseases of infectious etiology that lead to the destruction of the supporting tissues located around teeth or implants. Although both pathologies share several characteristics, it is also known that they show important differences which could be due to the release of particles and metal ions from the implant surface. The activation of the inflammasome pathway is one of the main triggers of the inflammatory process. The inflammatory process in patients who suffer periodontitis or peri-implantitis has been mainly studied on cells of the immune system; however, it is also important to consider other cell types with high relevance in the regulation of the inflammatory response. In that context, mesenchymal stromal cells (MSCs) play an essential role in the regulation of inflammation due to their ability to modulate the immune response. This study shows that the induction of NLRP3 and absent in melanoma 2 (AIM2) inflammasome pathways mediated by bacterial components increases the secretion of active IL-1β and the pyroptotic process on human alveolar bone-derived mesenchymal stromal cells (hABSCs). Interestingly, when bacterial components are combined with titanium ions, NLRP3 expression is further increased while AIM2 expression is reduced. Furthermore, decrease of NLRP3 or AIM2 expression in hABSCs partially reverses the negative effect observed on the progression of the inflammatory process as well as on cell survival. In summary, our data suggest that the progression of the inflammatory process in peri-implantitis could be more acute due to the combined action of organic and inorganic components.
- 16 July 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (8) , 826-841
Open AccessNLRP3 and AIM2 inflammasomes expression is modified by LPS and titanium ions increasing the release of active IL-1β in alveolar bone-derived MSCs
Periodontitis and peri-implantitis are inflammatory diseases of infectious etiology that lead to the destruction of the supporting tissues located around teeth or implants. Although both pathologies share several characteristics, it is also known that they show important differences which could be due to the release of particles and metal ions from the implant surface. The activation of the inflammasome pathway is one of the main triggers of the inflammatory process. The inflammatory process in patients who suffer periodontitis or peri-implantitis has been mainly studied on cells of the immune system; however, it is also important to consider other cell types with high relevance in the regulation of the inflammatory response. In that context, mesenchymal stromal cells (MSCs) play an essential role in the regulation of inflammation due to their ability to modulate the immune response. This study shows that the induction of NLRP3 and absent in melanoma 2 (AIM2) inflammasome pathways mediated by bacterial components increases the secretion of active IL-1β and the pyroptotic process on human alveolar bone-derived mesenchymal stromal cells (hABSCs). Interestingly, when bacterial components are combined with titanium ions, NLRP3 expression is further increased while AIM2 expression is reduced. Furthermore, decrease of NLRP3 or AIM2 expression in hABSCs partially reverses the negative effect observed on the progression of the inflammatory process as well as on cell survival. In summary, our data suggest that the progression of the inflammatory process in peri-implantitis could be more acute due to the combined action of organic and inorganic components.
- Open Access
- 29 August 2023
- Published by Wiley in Clinical Oral Implants Research
- Vol. 34 (12) , 1342-1353
Inflammasomes NLRP3 and AIM2 in peri‐implantitis: A cross‐sectional study
Background: Inflammasome components NLRP3 and AIM2 contribute to inflammation development by the activation of caspase‐1 and IL‐1β. They have not been yet evaluated in samples from patients with active peri‐implantitis. Thus, the aim of the present study is to analyze the expression of inflammasomes NLRP3 and AIM2 and subsequent caspase 1 and IL‐1β assessing the microenvironment of leukocyte subsets in samples from patients with active peri‐implantitis.Methods: Biopsies were collected from 33 implants in 21 patients being treated for peri‐implantitis. Biopsies from gingival tissues from 15 patients with healthy periodontium were also collected for control. These tissues were evaluated through conventional histological stainings. Then, immunohistochemical detection was performed to analyze NLRP3, AIM2, caspase‐1, and IL‐1β and markers of different leukocyte subsets. PCR for inflammasomes and related genes was also done.Results: This manuscript reveals a high immunohistochemical and mRNA expression of NLRP3 and AIM2 inflammasomes, caspase‐1, and IL‐1β in biopsies collected from human peri‐implantitis. The expression of the tested markers was significantly correlated with the increase in inflammatory infiltrate, probing depth, presence of biofilm, and bleeding on probing. In these peri‐implantitis lesions, the area of biopsy tissue occupied by inflammatory infiltrate was intense while the area occupied by collagen was significantly lower. In comparison with periodontal healthy tissues, the inflammatory infiltrate was statistically significantly higher in the peri‐implantitis biopsies and was mainly composed of plasma cells, followed by T and B lymphocytes.Conclusion: In human peri‐implantitis, chronic inflammation can be explained in part by the action of IL‐1β/caspase 1 induced through NLRP3 and AIM2 inflammasome activation.
- 29 August 2023
- Published by Wiley in Clinical Oral Implants Research
- Vol. 34 (12) , 1342-1353
Open AccessInflammasomes NLRP3 and AIM2 in peri‐implantitis: A cross‐sectional study
Background: Inflammasome components NLRP3 and AIM2 contribute to inflammation development by the activation of caspase‐1 and IL‐1β. They have not been yet evaluated in samples from patients with active peri‐implantitis. Thus, the aim of the present study is to analyze the expression of inflammasomes NLRP3 and AIM2 and subsequent caspase 1 and IL‐1β assessing the microenvironment of leukocyte subsets in samples from patients with active peri‐implantitis.Methods: Biopsies were collected from 33 implants in 21 patients being treated for peri‐implantitis. Biopsies from gingival tissues from 15 patients with healthy periodontium were also collected for control. These tissues were evaluated through conventional histological stainings. Then, immunohistochemical detection was performed to analyze NLRP3, AIM2, caspase‐1, and IL‐1β and markers of different leukocyte subsets. PCR for inflammasomes and related genes was also done.Results: This manuscript reveals a high immunohistochemical and mRNA expression of NLRP3 and AIM2 inflammasomes, caspase‐1, and IL‐1β in biopsies collected from human peri‐implantitis. The expression of the tested markers was significantly correlated with the increase in inflammatory infiltrate, probing depth, presence of biofilm, and bleeding on probing. In these peri‐implantitis lesions, the area of biopsy tissue occupied by inflammatory infiltrate was intense while the area occupied by collagen was significantly lower. In comparison with periodontal healthy tissues, the inflammatory infiltrate was statistically significantly higher in the peri‐implantitis biopsies and was mainly composed of plasma cells, followed by T and B lymphocytes.Conclusion: In human peri‐implantitis, chronic inflammation can be explained in part by the action of IL‐1β/caspase 1 induced through NLRP3 and AIM2 inflammasome activation.
- Open Access
- 29 January 2023
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 25 (2) , 370-380
Physico‐chemical and biological characterization of a new bovine bone mineral matrix available for human usage
Background: Anorganic bovine bone has been deeply studied for bone regeneration in the oral cavity. Different manufacturing processes can modify the final composition of the biomaterial and the responses that induce.Aim: To evaluate the physico‐chemical characteristics of a bovine bone mineral matrix and the clinical, radiographical, histological, and mRNA results after using it for maxillary sinus floor augmentation in humans.Materials and Methods: First, the physical–chemical characteristics of the biomaterial were evaluated by X‐ray powder diffraction, X‐ray fluorescence, and electron microscopy. A frequently used biomaterial with the same animal origin was used as comparator. Then, a clinical study was designed for evaluating clinical, radiographical, histological, and mRNA outcomes. Patients in need of two‐stage maxillary sinus floor augmentation were included in the study. Six months after the grafting procedure, a bone biopsy was collected for evaluation.Results: In terms of physico‐chemical characteristics, no differences were found between both biomaterials. Clinically, 10 patients were included in the study. After 6 months, clinical and radiographical data showed adequate outcomes for allowing implant placement. Histological, immunohistochemical and mRNA analyses showed that the biomaterial in use provides biological support to induce responses similar to those of other commonly used biomaterials.Conclusion: Bovine bone mineral matrix (Creos™ Xenogain) used as a single material for maxillary sinus floor augmentation shows adequate biological, clinical, and radiological outcomes. In fact, the results from this study are similar to those reported in the literature for another bovine bone‐derived biomaterial with whom it shares composition and micro‐ and nanoscale characteristics.
- 29 January 2023
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 25 (2) , 370-380
Open AccessPhysico‐chemical and biological characterization of a new bovine bone mineral matrix available for human usage
Background: Anorganic bovine bone has been deeply studied for bone regeneration in the oral cavity. Different manufacturing processes can modify the final composition of the biomaterial and the responses that induce.Aim: To evaluate the physico‐chemical characteristics of a bovine bone mineral matrix and the clinical, radiographical, histological, and mRNA results after using it for maxillary sinus floor augmentation in humans.Materials and Methods: First, the physical–chemical characteristics of the biomaterial were evaluated by X‐ray powder diffraction, X‐ray fluorescence, and electron microscopy. A frequently used biomaterial with the same animal origin was used as comparator. Then, a clinical study was designed for evaluating clinical, radiographical, histological, and mRNA outcomes. Patients in need of two‐stage maxillary sinus floor augmentation were included in the study. Six months after the grafting procedure, a bone biopsy was collected for evaluation.Results: In terms of physico‐chemical characteristics, no differences were found between both biomaterials. Clinically, 10 patients were included in the study. After 6 months, clinical and radiographical data showed adequate outcomes for allowing implant placement. Histological, immunohistochemical and mRNA analyses showed that the biomaterial in use provides biological support to induce responses similar to those of other commonly used biomaterials.Conclusion: Bovine bone mineral matrix (Creos™ Xenogain) used as a single material for maxillary sinus floor augmentation shows adequate biological, clinical, and radiological outcomes. In fact, the results from this study are similar to those reported in the literature for another bovine bone‐derived biomaterial with whom it shares composition and micro‐ and nanoscale characteristics.
- Open Access
- 17 November 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (11) , 1-12
GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β
Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-activating protein that promotes immune escape and dissemination in various cancers. However, if GARP affects the tumorigenicity and treatment resistance of sarcomas is not known. We show that GARP is expressed by human osteo-, chondro-, and undifferentiated pleomorphic sarcomas and is associated with a significantly worse clinical prognosis. Silencing of GARP in bone sarcoma cell lines blocked their proliferation and induced apoptosis. In contrast, overexpression of GARP promoted their growth in vitro and in vivo and increased their resistance to DNA damage and cell death induced by etoposide, doxorubicin, and irradiation. Our data suggest that GARP could serve as a marker with therapeutic, prognostic, and predictive value in sarcoma. We propose that targeting GARP in bone sarcomas could reduce tumour burden while simultaneously improving the efficacy of chemo- and radiotherapy.
- 17 November 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (11) , 1-12
Open AccessGARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β
Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-activating protein that promotes immune escape and dissemination in various cancers. However, if GARP affects the tumorigenicity and treatment resistance of sarcomas is not known. We show that GARP is expressed by human osteo-, chondro-, and undifferentiated pleomorphic sarcomas and is associated with a significantly worse clinical prognosis. Silencing of GARP in bone sarcoma cell lines blocked their proliferation and induced apoptosis. In contrast, overexpression of GARP promoted their growth in vitro and in vivo and increased their resistance to DNA damage and cell death induced by etoposide, doxorubicin, and irradiation. Our data suggest that GARP could serve as a marker with therapeutic, prognostic, and predictive value in sarcoma. We propose that targeting GARP in bone sarcomas could reduce tumour burden while simultaneously improving the efficacy of chemo- and radiotherapy.